THE EPIDEMIOLOGY OF AIDS: RECIPIENTS OF BLOOD AND BLOOD PRODUCTS

Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

THE EPIDEMIOLOGY OF AIDS: RECIPIENTS OF BLOOD AND BLOOD PRODUCTS

The Epidemiology of AIDS: Expression, Occurrence, and Control of Human Immunodeficiency Virus Type 1 Infection. Kaslow RA and Francis DP, eds. New York, Oxford University Press, p. 179-93, 1989.. Unique Identifier : AIDSLINE ICDB/90668117
Peterman T; Allen J; Center for Prevention Services, Freeway Park, CDC, Atlanta, GA; 30333

Abstract: Transfusion recipients are exposed to blood from only a few donors, whereas hemophiliacs (ie, clotting-factor recipients) have extensive donor exposure because clotting factor is concentrated from thousands of donors. Recipients of clotting factor have a seroprevalence rate 1,000 times that of transfusion recipients, the highest of all AIDS risk groups. The risk of infection for hemophiliacs and transfusion recipients, the natural history of persons infected by blood products, and prevention programs that have nearly eliminated HIV transmission to these groups are reviewed. Topics include clotting-factor concentrates, single-donor products, products of human plasma that have not transmitted infection, legal issues, and prevention (donor deferral, serologic screening, heat treatment of factor concentrates, changes in transfusion practices, and transmission from infected recipients). Transmission of HIV-1 by blood transfusions and clotting-factor concentrates has been nearly eliminated less than 4 yr after it was first described. However, 20,000 to 30,000 hemophiliacs and transfusion recipients already have been infected. Preventing AIDS in their sex partners requires identifying HIV-1 infected recipients and helping to avoid transmission to their sex partners. Preventing or postponing AIDS in persons already infected with HIV-1 depends on identification of those individuals who are appropriate candidates for chemoprophylaxis with zidovudine and other agents now available. (89 Refs)

Keywords: Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL/ *TRANSMISSION Blood Coagulation Factors/*THERAPEUTIC USE Blood Donors *Blood Transfusion Hemophilia/*THERAPY Human HIV Infections/PREVENTION & CONTROL/*TRANSMISSION HIV Seroprevalence HIV-1/*PATHOGENICITY Risk Factors Sexual Partners United States MONOGRAPH REVIEW REVIEW, TUTORIAL
901230
M90C3730

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .